Sodium zirconium cyclosilicate
Based on 1 Customer Validation
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.0%
- CAS. Nr.: 17141-74-1
- Formel: H6O9Si3.2Na.Zr
- Molecular Weight:371.50
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
Sodium zirconium cyclosilicate (ZS-9) is an inorganic cation exchange crystalline compound that has a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate has the exchange capacities for the divalent ions Ca2+ and Mg2+ are below 0.05 mEq/g, and a >25-fold selectivity for K+ over either Ca2+ or Mg2+[1]. Dissolution Precautions: Sodium zirconium cyclosilicate can be prepared as a 1 mg/mL suspension in water as a stock solution, aliquoted, and stored at -80°C. This product is essentially an insoluble inorganic crystal that exists as a solid in the gastrointestinal tract, adsorbing potassium ions (K+) through an ion exchange mechanism rather than through dissolution.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[2]
-
Dosage:2, 4, and 6 g/kg
-
Administration:Oral administration; daily, for 5 days
-
Result:Had 99% fecal recovery in rats.
Uptake and removal of potassium ions in a dose-dependent manner.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 17141-74-1
-
Appearance Solid
-
Molecular Weight 371.50
-
Formel H6O9Si3.2Na.Zr
-
Color White to off-white
-
SMILES
O[Si]1(O[Si](O)(O[Si](O)(O)O1)O)O.[Na].[Zr].[Na]
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686. [Content Brief]
[2]. Ash SR, et, al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Sodium zirconium cyclosilicate Related Classifications
HY-119572 Related Classifications
Powered by Bioz